Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 6
2004 2
2005 3
2006 1
2009 5
2010 2
2011 1
2014 1
2015 1
2016 3
2017 2
2018 2
2019 4
2020 9
2021 15
2022 5
2023 9
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
Askanase AD, D'Cruz D, Kalunian K, Merrill JT, Navarra SV, Cahuzac C, Cornelisse P, Murphy MJ, Strasser DS, Trokan L, Berkani O. Askanase AD, et al. Lancet Rheumatol. 2025 Jan;7(1):e21-e32. doi: 10.1016/S2665-9913(24)00246-7. Epub 2024 Nov 22. Lancet Rheumatol. 2025. PMID: 39586304 Clinical Trial.
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS.
Dall'Era M, Kalunian K, Solomons N, Truman M, Hodge LS, Yap E, Askanase AD. Dall'Era M, et al. Among authors: askanase ad. Lupus Sci Med. 2024 Nov 9;11(2):e001319. doi: 10.1136/lupus-2024-001319. Lupus Sci Med. 2024. PMID: 39521453 Free PMC article. Clinical Trial.
Lupus clinical trials and the promise of future therapies.
Khalili L, Tang W, Askanase AD. Khalili L, et al. Among authors: askanase ad. Rheumatol Immunol Res. 2023 Sep 27;4(3):109-114. doi: 10.2478/rir-2023-0018. eCollection 2023 Sep. Rheumatol Immunol Res. 2023. PMID: 37781678 Free PMC article. No abstract available.
Meeting report: the ALPHA project: a stakeholder meeting on lupus clinical trial outcome measures and the patient perspective.
Buie J, Bloch L, Morand EF, van Vollenhoven RF, Werth VP, Touma Z, Lipsky P, Kalunian K, Askanase AD, Ines L, Reed C, Son M, Franson T, Costenbader K, Schanberg LE. Buie J, et al. Among authors: askanase ad. Lupus Sci Med. 2023 Feb;10(1):e000901. doi: 10.1136/lupus-2023-000901. Epub 2023 Feb 14. Lupus Sci Med. 2023. PMID: 37537705 Free PMC article.
73 results